Akebia Therapeutics Inc. (NASDAQ:AKBA) fell 2.2% on Friday . The stock traded as low as $7.90 and last traded at $7.91, with a volume of 80,532 shares changing hands. The stock had previously closed at $8.09.

Several brokerages have weighed in on AKBA. Credit Suisse Group AG reissued a “hold” rating on shares of Akebia Therapeutics in a research report on Tuesday, July 12th. Zacks Investment Research lowered shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 24th. HC Wainwright restated a “buy” rating on shares of Akebia Therapeutics in a report on Tuesday, August 23rd. Brean Capital restated a “buy” rating on shares of Akebia Therapeutics in a report on Sunday, May 8th. Finally, Morgan Stanley restated a “buy” rating on shares of Akebia Therapeutics in a report on Sunday, May 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Akebia Therapeutics presently has a consensus rating of “Buy” and an average price target of $15.75.

The firm’s market capitalization is $148.41 million. The stock has a 50-day moving average of $8.46 and a 200 day moving average of $8.46.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.38. Equities research analysts anticipate that Akebia Therapeutics Inc. will post ($3.73) earnings per share for the current year.

An institutional investor recently raised its position in Akebia Therapeutics stock. Connor Clark & Lunn Investment Management Ltd. raised its stake in Akebia Therapeutics Inc. (NASDAQ:AKBA) by 9.5% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 97,925 shares of the biopharmaceutical company’s stock after buying an additional 8,500 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.54% of Akebia Therapeutics worth $1,265,000 at the end of the most recent reporting period.

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.